IHS Chemical Week

Regions :: North America :: U.S.

Sun Pharma and Lupin receive FDA approvals for generic Cymbalta

7:36 AM MST | December 12, 2013 | Natasha Alperowicz

Sun Pharmaceutical Industries (Mumbai) and Lupin (Mumbai), two leading pharma producers for the global markets, announced today that their US subsidiaries have gained FDA approvals for duloxetine hydrochloride delayed release drug, the generic version of the antidepressant  Cymbalta.  Cymbalta delayed-release capsule 20, 30 and 60 mg is an Eli Lilly product with last year’s sales in the United States approaching $5.5 billion.   Sun Pharma in the year ended 31 March 2013 reported sales of $2.1 billion of which $1.1 billion were in the US...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa